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In the present issue of Critical Care, Kinasewitz and
colleagues report on the measurement of various markers of
coagulation activation in patients with severe sepsis that
were included in the PROWESS trial, the pivotal phase III
clinical trial of recombinant activated protein C [1].
Kinasewitz and colleagues underscore the notion that severe
infection or sepsis is almost invariably associated with
activation of coagulation. This coagulation activation spans a
wide spectrum, from a subtle prohemostatic response only
detectable with sensitive molecular markers of coagulation
activation, to full-blown disseminated intravascular
coagulation (DIC). DIC is characterized by simultaneous
widespread microvascular thrombosis and profuse bleeding
from various sites [2].
How relevant is coagulation for the
pathogenesis of sepsis?
There are several lines of evidence supporting an important
pathogenetic role of DIC in the development of sepsis-
associated organ failure [3]. Histological studies of tissues
from septic patients may show diffuse bleeding at various sites,
hemorraghic necrosis of tissue, microthrombi in small blood
vessels and thrombi in mid-size and larger arteries and veins.
Most experimental animal studies of DIC show fibrin
deposition in various organs. For example, experimental
bacteremia or endotoxemia causes intravascular and
extravascular fibrin deposition in the kidneys, the lungs, the
liver, the brain and various other organs. Amelioration of the
hemostatic defect by various interventions in these
experimental models appears to improve organ failure and, in
most cases, to reduce mortality. Finally, clinical studies
support the notion of coagulation as an important
denominator of clinical outcome.
DIC has been shown to be a strong and independent
predictor of mortality in patients with sepsis and severe
trauma. Clinical studies aimed at intervening in the
coagulation cascade in patients with severe sepsis have
recently been completed. In particular, the administration of
recombinant human activated protein C has been
demonstrated to be effective in reducing 28-day mortality [4].
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Abstract
Sepsis almost invariably leads to hemostatic abnormalities, ranging from insignificant laboratory
changes to severe disseminated intravascular coagulation. There is compelling evidence from clinical
and experimental studies that disseminated intravascular coagulation is involved in the pathogenesis of
microvascular dysfunction and contributes to organ failure. Data from the PROWESS phase III clinical
trial of recombinant activated protein C in patients with severe sepsis confirm this notion and
demonstrate that the vast majority of patients with severe sepsis have increased markers for systemic
coagulation activation, decreased physiological anticoagulant proteins and depressed fibrinolysis.
There is no correlation between the type of microorganism that has caused the infection and the
presence or severity of the coagulation disorder.
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The fact that other interventions such as antithrombin
concentrate or recombinant tissue factor pathway inhibitor
were less successful [5,6], however, may suggest that the
beneficial effect of recombinant activated protein C may also
rely on factors beyond coagulation. In fact, a marked interplay
between coagulation and inflammatory activation at the level
of the protein C system exists, and activated protein C has
been shown to affect inflammation in vitro and in several in
vivo models [7]. On the contrary, the optimal clinical effect of
activated protein C was calibrated using a coagulation
parameter (i.e. D-dimer), and patients with overt DIC
(according to newly developed international criteria) have a
relatively larger benefit of activated protein C treatment [8,9].
Taken together, coagulation (in conjunction with
inflammation) may well be at the basis of the pathogenesis of
severe sepsis.
Coagulation and inflammation biomarkers in
patients with severe sepsis
Kinasewitz and colleagues, in the present issue of Critical
Care, show plasma levels of several biomarkers of
coagulation activation, anticoagulant pathways, fibrinolysis,
inflammation and endothelial cell injury in patients with severe
sepsis [1]. They indeed show that virtually all patients had
activated coagulation, as reflected by increased levels of
D-dimer and the thrombin–antithrombin complexes. In
addition, the vast majority of these patients had coagulation
activation that was detectable with less sensitive and more
routinely available coagulation assays, such as the
prothrombin time, and by measurement of antithrombin and
protein C. Also, a depression of fibrinolytic activity was noted
in about 50% of patients. The changes in coagulation
parameters were strongly related to inflammatory activity and
to markers of endothelial cell injury. The data confirm
previous studies that nonsurviving patients have a more
marked activation of inflammation and coagulation, and a
more severely depressed anticoagulant defense.
Causative microorganism and coagulation
activation
Most textbooks state that severe activation of coagulation or
DIC is most commonly associated with infection with Gram-
negative bacteria. However, systematic surveys show that
Gram-positive bacteria may cause fulminant coagulation
activation as often as do Gram-negative bacteria [10]. Other
microorganisms, including viruses and parasites (such as
malaria), may also cause DIC, which can dominate the
clinical picture or at least play a significant role in the
pathogenesis of the severe infection [11,12]. The report by
Kinasewitz and colleagues also indicates that activation of
coagulation in patients with severe sepsis occurs regardless
of the causative microorganism. The only exception in the
article by Kinasewitz and colleagues may be represented by
the patients with a fungal infection. However, when corrected
for disease severity, it is probable that this group would be
comparable with patients with bacterial infections.
It is known that specific microorganisms may have a specific
impact on the coagulation system. Viruses, such as
cytomegalovirus, may cause microangiopathic thrombosis
and vasculitis on top of their ability to cause activation of
coagulation [3]. Gram-positive bacteria, such as certain
strains of Streptococcus pyogenes, may cause a marked
activation of the contact system [13]. A significant difference
in the ability to induce inflammatory and coagulation
activation between endotoxin preparations of various
microorganisms was also noted [14]. Nevertheless, in a
mixed group of patients with severe sepsis, as was admitted
to the PROWESS study, in which more than 20 different
causative microorganisms were isolated, no major
differences in biomarkers reflecting activation of coagulation
and of inflammation between groups of microorganisms were
observed. This result seems to support the hypothesis that
the intensity of the inflammatory or coagulation response is
dependent on other factors, such as host-dependent
circumstances or the site of the infection, rather than on the
causative microorganism [15].
In conclusion, activation of coagulation, impairment of
physiological anticoagulant pathways and depression of
fibrinolysis, along with inflammatory activation, are seen in the
vast majority of patients with severe sepsis. The severity of
the inflammatory coagulative response does not seem to
have a relationship with the causative microorganism. This
once again underscores the notion that the host response
rather than the underlying infection is responsible for the
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